Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon, Ltd.

http://www.biocon.com/

Latest From Biocon, Ltd.

India FY22 Earnings: Everyone’s Talking Of Big Spikes In Input, Logistics Costs

The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.

Commercial India

Viatris And Biocon Launch Bevacizumab Biosimilar In Canada

Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.

Biosimilars Launches

Can Roche’s Phesgo Mirror UK Adoption Trend in India?

Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?

Commercial Pricing Strategies

COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India

A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters

Commercial Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Distributors
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Biocon Sdn Bhd.
    • Biocon Limited
    • Biocon Biologics India Ltd
    • Bicara Therapeutics
UsernamePublicRestriction

Register